MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment; TecDAX) intends to place up to 490,133 new shares through an accelerated book building process to institutional investors. The Management and Supervisory Boards of MorphoSys AG decided today to increase the Company's equity capital against contribution in cash exempting preemptive rights. WestLB AG acts as Sole Lead Manager of the transaction.
The issue proceeds will be used to capitalize on existing and future expansion opportunities to accelerate internal and external sales growth primarily in MorphoSys' activities in the field of research antibodies.
To ensure a timely delivery of shares to new investors, WestLB has entered into share loan agreements with a major strategic shareholder and members of the Management and Supervisory Boards of MorphoSys AG.
This announcement is not being issued in the United States of America and should not be distributed to United States Persons or Publications with a general circulation in the United States. This announcement does not constitute an offer of securities for sale in the United States. The securities offered have not been registered under the U.S. Securities Act of 1933, as amended (the 'Securities Act') and may not be sold in the United States absent registration or an exemption from registration under the Securities Act.